Skip to content

Cleansing Efficacy of Cosmetic Product

Cleansing Efficacy of Cosmetic Products - Particular Matter Model

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06956625
Acronym
Cleanser
Enrollment
24
Registered
2025-05-04
Start date
2025-05-08
Completion date
2025-05-09
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Skin

Brief summary

The aim of this study is to investigate the cleansing effect of one cosmetic product containing Mitopure against a particular matter model pollutant in comparison to an untreated control.

Interventions

OTHERTopical cosmetic cleanser

After applying the model pollutant, the test area will be topically cleaned with the active cosmetic cleanser with Mitopure.

OTHERTopical tap water

After applying the model pollutant, the test area will be topically cleaned with tap water (control).

Sponsors

SGS proderm GmbH
CollaboratorUNKNOWN
Amazentis SA
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Two test areas will be defined on both forearms. Area 1 will be located on the right forearm; Area 2 will be located on the left forearm. Treatments will be randomly and balanced assigned to the test areas.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent to participate in the study * Willingness to actively participate in the study and to come to the scheduled visits * Female and/or male * From 18 to 70 years of age * Healthy skin in the test area * Skin type on Fitzpatrick scale: I, II or III

Exclusion criteria

* Female subjects: Pregnancy or lactation * Drug addicts, alcoholics * AIDS, HIV-positive or infectious hepatitis * Conditions which exclude a participation or might influence the test reaction/evaluation * Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area * Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years * Active skin disease at the test area * Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation * Any topical medication at the test area within the last 4 weeks prior to the start of the study and during the study * Documented allergies to cosmetic products and/or ingredients

Design outcomes

Primary

MeasureTime frameDescription
Luminosity (L)Before pollutant application (t0), immediately after evaporation of the applied pollutant (t1), and 20 minutes after product rinse-off (t2)Luminosity in test area assessed by HiRIS (High Resolution Imaging System) image analysis will be used to quantify cleaning efficacy.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026